fbpx
QQQ
+ 2.58
328.93
+ 0.78%
DIA
+ 2.29
343.25
+ 0.66%
SPY
+ 2.93
416.17
+ 0.7%
TLT
-0.69
140.61
-0.49%
GLD
+ 1.55
168.49
+ 0.91%

3 Pharmaceutical ETFs That Could Be Due For A Rebound

April 15, 2021 5:28 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
3 Pharmaceutical ETFs That Could Be Due For A Rebound

These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound.

Support is a large concentration of buyers who have gathered around the same price level. At support levels, there is more demand for the stock than there is supply.

Downtrends end when they reach support levels.

Many times, stocks rally off of support levels. This happens when some of the buyers become more aggressive. They don’t want the other buyers to get ahead of them in line. They decide to pay higher prices.

This forces the stock into rally mode.

See Also: 3 Short Squeeze Candidates In The Media Sector

The SPDR S&P Pharmaceuticals ETF (NYSE:XPH) has dropped to the $47.85 level. This level was support in November and December. It was the base for a large move higher into January. It could happen again.

xph.png

The Global X Cannabis ETF (NYSE:POTX) has reached the $14 level once again. After finding support at this level in January and March, the ETF rallied. There’s a chance it happens again.

potx.png

 

The Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (NYSE:PILL) has found support at the $19.50 level. This level was support in November and December. It was the base for a significant move higher.

pill.png


Related Articles

Heading Into The Election, Traders Are Still Betting On Tech

If the first three quarters of 2020 have been any indication, the final three months of the year will more than likely hold its fair share of surprises. That being said, trends among Direxion’s most popular leveraged funds reveal how traders are positioning themselves heading into election season. read more

3 Leveraged Healthcare ETFs Soaring This Month

With Earnings On Tap, A Stir In This Leveraged Pharmaceuticals ETF

It Could Be Time For This Pharma ETF